Table 1. Summary table of S. Typhi collection.
| Country | Total | 4.3.1 (%) | MDR (%) | Number of QRDR mutations | ||
|---|---|---|---|---|---|---|
| None (%) | One or two (%) | Three (%) | ||||
| South Asia | 384 | 313 (81.5%) | 100 (26%) | 18 (4.7%) | 316 (82.3%) | 50 (13%) |
| Afghanistan | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) |
| Bangladesh | 33 | 17 (51.5%) | 8 (24.2%) | 2 (6.1%) | 31 (93.9%) | 0 (0%) |
| India | 191 | 151 (79.1%) | 6 (3.1%) | 5 (2.6%) | 143 (74.9%) | 43 (22.5%) |
| Nepal | 3 | 1 (33.3%) | 0 (0%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) |
| Pakistan | 156 | 143 (91.7%) | 85 (54.5%) | 10 (6.4%) | 140 (89.7%) | 6 (3.9%) |
| South East Asia | 10 | 2 (80%) | 0 (0%) | 7 (70%) | 3 (30%) | 0 (0%) |
| Indonesia | 3 | 0 (0%) | 0 (0%) | 3 (100%) | 0 (0%) | 0 (0%) |
| Malaysia | 1 | 1 (100%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| Myanmar | 2 | 1 (50%) | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) |
| Philippines | 4 | 0 (0%) | 0 (0%) | 4 (100%) | 0 (0%) | 0 (0%) |
| Middle East | 4 | 2 (50%) | 1 (25%) | 2 (50%) | 2 (50%) | 0 (0%) |
| Iraq | 3 | 1 (33.3%) | 0 (0%) | 2 (66.7%) | 1 (33.3%) | 0 (0%) |
| UAE | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) |
| East Africa | 21 | 18 (85.7%) | 11 (52.4%) | 12 (57.1%) | 9 (42.9%) | 0 (0%) |
| Ethiopia | 1 | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Mozambique | 1 | 1 (100%) | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Rwanda | 1 | 1 (100%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| Tanzania | 4 | 4 (100%) | 2 (50%) | 2 (50%) | 2 (50%) | 0 (0%) |
| Uganda | 4 | 4 (100%) | 0 (0%) | 0 (0%) | 4 (100%) | 0 (0%) |
| Zimbabwe | 10 | 8 (80%) | 8 (80%) | 8 (80%) | 2 (20%) | 0 (0%) |
| West Africa | 11 | 0 (0%) | 3 (27.3%) | 8 (72.7%) | 3 (27.3%) | 0 (0%) |
| Angola | 2 | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) |
| Ghana | 2 | 0 (0%) | 1 (50%) | 2 (100%) | 0 (0%) | 0 (0%) |
| Nigeria | 6 | 0 (0%) | 2 (33.3%) | 3 (50%) | 3 (50%) | 0 (0%) |
| Sierra Leone | 1 | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Central Asia | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| China | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| North Africa | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| Egypt | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| Europe | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| Greece | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| South America | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| Peru | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| North America | 1 | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| USA | 1 | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| No Travel | 39 | 15 (38.5%) | 5 (12.8%) | 19 (48.7%) | 18 (46.2%) | 2 (5.1%) |
| No Travel Information | 45 | 30 (66.7%) | 9 (20%) | 9 (20%) | 32 (71.1%) | 4 (8.9%) |
Isolates from cases with reported travel to multiple countries not included in table.
UAE: United Arab Emirates
MDR: Multi-drug resistance
QRDR: Quinolone resistance determining region